关于使用长效抗逆转录病毒药物治疗和预防 HIV-1 的共识建议:经美国艾滋病医学学会、美国临床药学院、加拿大艾滋病和病毒性肝炎药剂师网络、欧洲艾滋病临床学会和传染病药剂师学会认可。

IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Pharmacotherapy Pub Date : 2024-07-01 DOI:10.1002/phar.2922
Elizabeth M Sherman, Allison L Agwu, Juan Ambrosioni, Georg M N Behrens, Carolyn Chu, Lauren F Collins, Humberto R Jimenez, David E Koren, Leslie McGorman, Nancy N Nguyen, Melanie R Nicol, Neha Sheth Pandit, Natacha Pierre, Kimberly K Scarsi, Gary F Spinner, Alice Tseng, Jeremy D Young, Melissa E Badowski
{"title":"关于使用长效抗逆转录病毒药物治疗和预防 HIV-1 的共识建议:经美国艾滋病医学学会、美国临床药学院、加拿大艾滋病和病毒性肝炎药剂师网络、欧洲艾滋病临床学会和传染病药剂师学会认可。","authors":"Elizabeth M Sherman, Allison L Agwu, Juan Ambrosioni, Georg M N Behrens, Carolyn Chu, Lauren F Collins, Humberto R Jimenez, David E Koren, Leslie McGorman, Nancy N Nguyen, Melanie R Nicol, Neha Sheth Pandit, Natacha Pierre, Kimberly K Scarsi, Gary F Spinner, Alice Tseng, Jeremy D Young, Melissa E Badowski","doi":"10.1002/phar.2922","DOIUrl":null,"url":null,"abstract":"<p><p>Five long-acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV-1 prevention or treatment-cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV-1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV-1 treatment and prevention. In addition, future areas of research are also identified and discussed.</p>","PeriodicalId":20013,"journal":{"name":"Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists.\",\"authors\":\"Elizabeth M Sherman, Allison L Agwu, Juan Ambrosioni, Georg M N Behrens, Carolyn Chu, Lauren F Collins, Humberto R Jimenez, David E Koren, Leslie McGorman, Nancy N Nguyen, Melanie R Nicol, Neha Sheth Pandit, Natacha Pierre, Kimberly K Scarsi, Gary F Spinner, Alice Tseng, Jeremy D Young, Melissa E Badowski\",\"doi\":\"10.1002/phar.2922\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Five long-acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV-1 prevention or treatment-cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV-1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV-1 treatment and prevention. In addition, future areas of research are also identified and discussed.</p>\",\"PeriodicalId\":20013,\"journal\":{\"name\":\"Pharmacotherapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/phar.2922\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/phar.2922","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目前,世界上有五种长效(LA)抗逆转录病毒药物(ARV)可在少数国家用于预防或治疗 HIV-1--卡博替拉韦(Cabotegravir)、利匹韦林(rilpivirine)、来那卡韦(lenacapavir)、伊巴利珠单抗(ibalizumab)和达匹韦林(dapivirine)。在常规临床实践中使用 LA 抗逆转录病毒药物需要对目前的 HIV-1 预防、治疗和服务提供框架进行重大变革。鉴于 LA 抗逆转录病毒药物的新颖性、复杂性以及安全和最佳使用 LA 抗逆转录病毒药物所需的跨学科要求,有关使用 LA 抗逆转录病毒药物的共识建议将有助于临床医生优化这些药物的使用。这些建议旨在为临床使用 LA 抗逆转录病毒药物治疗和预防 HIV-1 提供指导。此外,还确定并讨论了未来的研究领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists.

Five long-acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV-1 prevention or treatment-cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV-1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV-1 treatment and prevention. In addition, future areas of research are also identified and discussed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmacotherapy
Pharmacotherapy 医学-药学
CiteScore
7.80
自引率
2.40%
发文量
93
审稿时长
4-8 weeks
期刊介绍: Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports on pharmacokinetic, bioavailability, and drug interaction studies, clinical trials, investigations of specific pharmacological properties of drugs, and related topics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信